Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...
Reexamination Certificate
2008-05-20
2008-05-20
Henley, III, Raymond J (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Phosphorus containing other than solely as part of an...
Reexamination Certificate
active
07375097
ABSTRACT:
The present invention relates to a method of increasing Adenosine Triphosphate levels in a mammal wherein 2-(carbamimidoyl-methyl-amino)ethoxyphosphonic acid inhibits the leakage of the Adenosine Triphosphate-dependant enzyme Creatine Kinase. Via the inhibition of Creatine Kinase leakage, Adenosine Triphosphate is not utilized in the conversion of creatine to phosphocreatine, thereby making it available for use in muscular contractions. The increase in availability leads to longer endurance and more forceful muscular contractions.
REFERENCES:
patent: 6602512 (2003-08-01), Cavazza
patent: 2005/0192183 (2005-09-01), Gastner et al.
patent: 6401 (1968-11-01), None
International Search Report, PCT/CA2006/001427, International filing date of Aug. 30, 2006, Aplodan Formulations Ltd. et al.
Van Beekvelt MC et al. Performance of near-infrared spectroscopy in measuring local O(2) consumption and blood flow in skeletal muscle. J Appl Physiol. Feb. 2001;90(2):511-9.
Verkerke GJ et al. Precision, comfort and mechanical performance of the Quadriso-tester, a quadriceps force measuring . . . Med Biol Eng Comput. May 2003;41(3):283-9. (Abstract).
Holm P et al. Endurance training of respiratory muscles improves cycling performance in fit young cyclists.BMC Physiol. May 6, 2004;4:9.
Wassermann K et al. Determination of the anaerobic threshold by gas exchange: biochemical considerations, methodology . . . Z Kardiol. 1994;83 Suppl 3:1-12. (Abstract).
Cole MA, Brown MD. Response of the human triceps surae muscle to electrical stimulation during varying levels of blood . . . Eur J Appl Physiol. May 2000;82(1-2):39-44. (Abstract).
Pincivero DM et al. Assessment of the reliability of high-intensity quadriceps femoris muscle fatigue. Med Sci Sports Exerc. Feb. 2001;33(2):334-8. (Abstract).
Nowak DA, Hermsdorfer J. [Analysis of grip force during object manipulation. Method for the objective . . . ] Nervenarzt. Aug. 2004;75(8):725-33. Review, German. (Abstract).
Hespel P et al. Creatine supplementation: exploring the role of the creatine kinase/phosphocreatine system in . . . Can J Appl Physiol. 2001;26 Suppl:S79-102. Review. (Abstract).
Boutellier U. Respiratory muscle fitness and exercise endurance in healthy humans. Med Sci Sports Exerc. Jul. 1998;30(7): 1169-72.
Marzo A, Ghirardi P. Distribuzione sucellulare del creatinolo 0-fosfato nel cuore isolto di ratto. Boll. Soc. It. Biol. Sper., 1974 50: 1601-1605. (and translation to English).
Marzo A. Ghirardi P. Pharmacokinetics of creatinol O-phosphate. Plasma turnover, fate and excretion rate, subcellular distribution . . . Arzneimittelforschung. 1979:29(9a):1452-6.
Ferrari G. Casagrande C. Synthesis and chemical properties of N- and O-phosphorylated derivatives of creatinol. Arzneimittelforschung. 1979;29(9a):1446-9.
Godfraind T. Godfrain-De Becker A. Creatinol O-phosphate is a potential intracellular buffer. Proc of the B.P.S. Sep. 1980. (Abstract).
Melloni GF et al. Acute clinical tolerance of creatinol O-phosphate. Arzneimittelforschung. 1979:29(9a):1447-9.
Nicaise J. Creatinol O-phosphate (COP) and muscular performance: a controlled clinical trial. Curr Ther Res Clin Exp. Jun. 1975;17(6):531-4.
Curti PC. Camerota G. Controllo clinco di farmaci e medicamenti. Progr. Med., Roma 30:977, 1974. (and translation to English).
Possibilità di supporto energetico nell'actività sportivà. Stampa Medica Flash. May 1986 Anno 1 (4):1-5. (and translation to English).
De Gasperi R et al. Influenza del creatinolo o-fosfato sulla contrazione muscolare aspetti biochimici. Archivio Medicina Interna. 1981 3:351-358. (and translation to English).
Gaggino R, et al G. Aspetti metabolici delle prestatzioni sportive anaerobiche lattacide massimali. Medicina Dello Sport. 1984 37:85-92. (and translation to English).
Spengler CM, Boutellier U. Breathless Legs? Consider Training Your Respiration. News Physiol Sci. Apr. 2000;15:101-105.
Aplodan® effervescente ad alte dosi. Prescrivibile S.S.N. negli stati di insufficienza della muscolaturea striata. Simes. A (and translation to English), date unavailable.
Aplodan®. Protegge la fibra muscolare dallo stress ipossico. Aumenta la resistenza alla fatica. Simes. B. (and translation to English), date unavailable.
Aplodan®. Protegge la fibra muscolare dallo stress ipossico. Aumenta la resistenza alla fatica. Simes. C. (and translation to English), date unavailable.
Aplodan®. Simes. D. (and translation to English), date unavailable.
Aplodan®. Astra-Simes S.p.A. D (and translation to English), date not provided.
Croche G. Phosphatase activity of guinea-pig tissues on Creatinol O-phosphate in vitro. J. Pharm. Pharmac. 1971 24:742-743.
Ferrini R, Miragoli G. Protective effect of creatinol O-phosphate (COP) on some experimental arrhythimias in vitro and in vivo. Arzneimittelforschung. 1979;29(9a):1475-7.
Ferrini R, Miragoli G. Protective effect of creatinol O-phosphate (COP) on ventricular fibrillation and death induced by . . . Arzneimittelforschung. 1979;29(9a):1473-4.
Toxicity Profile: Creatinol O-phosphate and its sodium salt. Bibra Internatioal Ltd. Surrey UK. 2002.
Creatinolfosfate. Index Nominum International Drug Discovery. Swiss Pharmaceutical Society. Eds. Medpharm Scientific Publishers. Stuttgart. 2004. p. 323.
Muller NF, Dessing RP Eds. Aplodan, European Drug Index. European Society of Clinical Pharmacy. Deutscher Apother. Verlong. Stuttgart. 1997. p. 91.
Sweetman EC. Martindale: The Complete drug Reference 32nd Ed. London Pharmaceutical Press 2002. p. 1601.
Barlattani M et al. Creatinol O-phosphate therapy in patients with inadequate coronary circulation. Double-blind clinical trial. Arzneimittelforschung. 1979;29(9a):1483-5.
Botti G, Bonatti V. Preliminary report on electrophysiological effectiveness of creatinol O-phosphate (COP) in human subjects. Arzneimittelfroschung. 1979;29(9a):1491-4.
Cadel A et al. Antiarrhythmic effectiveness of creatinol O-phosphate in man. Arzneimittelforschung. 1979;29(9a):1485-7.
Godfraind T et al. The action of creatinol O-phosphate on the inotropic effect of isoprenaline in isolated rat atria and in . . . Arzneitmittelforschung. 1979;29(9a):1465-7.
Godfraind T, Saleh MM. Action of creatinol-O-phosphate on the contractility changes evoked by hypoxia and ischemia in rat . . . Arzneimittelforschung. 1984;34(9):968-72.
Godfraind T, Sturbois X. An analysis of the reduction of creatinol O-phosphate of the myocardial lesions evoked by isoprenaline . . . Arzneimittelforschung. 1979;29(9a):1457-64.
Godfraind T. Concepts leading to the development of an anti-ischemic drug. Introductory remarks. Arzneimittelforschung. 1979;29(9a):1445.
Godfraind T et al. Ionic changes evoked by isoprenaline in rat hearts in vivo and in vitro and their reduction by creatinol . . . Arzneimittelforschung. 1979;29(9a):1468-70.
Godfraind T. Sturbois X. The prevention of creatinol O-phosphate of myocardial lesions evoked by isoprenaline. Arch Int Pharmacodyn Ther. Feb. 1979;237(2):288-97.
Sardini D et al. Analytical aspects of Creatinol-o-phosphate. II Farmaco- Ed. Pr. 26(3):194-202, date not provided.
Knippel M et al. Effects of creatinol O-phosphate on serum enzymes in acute myocardial infarction. Arzneimittelforschung. 1979;29(9a):1480-2.
Marchetti G, Merlo L. Effects of creatinol-O-phosphate (COP) on haemodynamics and cardiac metabolism in conscious and . . . Arzneimittelforschung. 1978;28(10):1708-11.
Marchetti G et al. Effects of creatinol o-phosphate on the isolated and in situ heart. Arch Int Pharmacodyn Ther. Jun. 1971;191(2):337-44.
Marzo A, Ghirardi P. Pharmacological and toxicological properties of creatinol O-phosphate. A review. Arzneimittelforschung. 1979;29(9a):1449-52. Review.
Marzo A, Ghirardi P. Protective action of creatinol O-phosphate against serum CPK activity enhanced by isoprenaline in the rat. Arzneimittelforschung. 1979;29(9a):1471-3.
Marzo A et al. Absorption, distribution and urinary excretion of creatinol O-phosphate ( 14 C) in the guinea-pig: Arch Int Pharmacodyn Ther. Aug. 1971;192(2):378-92.
Olsen JI et al. A 31P NMR spectroscopy study ofXenopus laevisheart p
Chaudhuri Shan
Peters Jason R.
Ramsbottom James D.
Aplodan Formulations Ltd.
Fitzpatrick ,Cella, Harper & Scinto
Henley, III Raymond J
LandOfFree
Increasing ATP availability by inhibition of creatine kinase... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Increasing ATP availability by inhibition of creatine kinase..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Increasing ATP availability by inhibition of creatine kinase... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2769597